Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gastrointestinal Cancers
•
Medical Oncology
Would you ever omit adjuvant therapy for rectal cancer in patients who underwent primary resection (TME), without any neoadjuvant therapy?
What about T3N0 disease? Would you use a recurrence score to help inform decisions?
Related Questions
What are your top takeaways from ASCO GI 2024?
How would you manage a positive margin after APR for a patient who received neoadjuvant CAPOX alone due to previous remote prostate cancer radiation?
How would you treat a patient with a synchronous T1N2 non-small cell lung cancer and a T3N1 mid-rectal adenocarcinoma (MMR intact)?
Is there strong evidence to use TMB found in circulating tumor DNA to guide the use of ICI in metastatic colon cancer?
Would you recommend off-label use of chemoimmunotherapy for metastatic anal squamous cell cancer?
Would you ever use a PET dotatate CT to monitor response of a GEP-NEN that is SSTR positive?
How would you treat an MSI-H metastatic cholangiocarcinoma found on liquid biopsy?
How do you approach elderly patients with HER2+ IHC 3+ metastatic pancreatic adenocarcinoma?
Would you treat a patient with a pancreatic head mass based on common bile duct brushings suggestive of malignancy, with repeated negative EUS biopsy?
How long do you treat with immunotherapy patients with MSI-high T4B initially unresectable colon adenocarcinoma?